{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T07:13:23Z","timestamp":1683184403568},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s00105-005-1006-6","type":"journal-article","created":{"date-parts":[[2005,8,16]],"date-time":"2005-08-16T09:02:28Z","timestamp":1124182948000},"page":"819-830","source":"Crossref","is-referenced-by-count":4,"title":["Etanercept"],"prefix":"10.1007","volume":"56","author":[{"given":"G.","family":"Wozel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1006_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.1780070113","volume":"7","author":"Blumberg","year":"1964","unstructured":"Blumberg BS, Bunim JJ, Calkins E et al. (1964) ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 7:93\u201397","journal-title":"Arthritis Rheum"},{"key":"1006_CR2","unstructured":"Bruce IN (2003) Psoriatic arthritis: clinical features. In: Hochberg MC, Silman AJ, Smolen JS et al. (eds) Rheumatology, 3rd edn. Elsevier, London, pp 1241\u20131252"},{"key":"1006_CR3","doi-asserted-by":"crossref","unstructured":"Chambers C, Johnson D, Jones KL (2005) Safety of anti-TNF-\u03b1 medications in pregnancy. J Am Acad Dermatol [Suppl] 52:196","DOI":"10.1016\/j.jaad.2004.10.792"},{"key":"1006_CR4","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","volume":"39","author":"Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Mejias E et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriasic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39:2013\u20132020","journal-title":"Arthritis Rheum"},{"key":"1006_CR5","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2165\/00003495-200262170-00012","volume":"62","author":"Culy","year":"2002","unstructured":"Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493\u20132537","journal-title":"Drugs"},{"key":"1006_CR6","unstructured":"AHFS Drug information (2003) Etanercept. American Society of Health-System Pharmacists, Bethesda, pp 3607\u20133613"},{"key":"1006_CR7","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/mjd.2003.554","volume":"49","author":"Goffe","year":"2003","unstructured":"Goffe B, Cather JC (2003) Etanercept: an overview. J Am Acad Dermatol 49:S105\u2013S111","journal-title":"J Am Acad Dermatol"},{"key":"1006_CR8","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","volume":"139","author":"Gottlieb","year":"2003","unstructured":"Gottlieb AB, Metheson RT, Lowe N et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627\u20131632","journal-title":"Arch Dermatol"},{"key":"1006_CR9","doi-asserted-by":"crossref","first-page":"P146","DOI":"10.1016\/j.jaad.2003.10.508","volume":"50","author":"Gottlieb","year":"2004","unstructured":"Gottlieb AB, Gordon K, Wang A, Zitnik R (2004) Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response. J Am Acad Dermatol 50:P146","journal-title":"J Am Acad Dermatol"},{"key":"1006_CR10","unstructured":"Gottlieb AB (2003) Etanercept for treatment of psoriasis and psoriatic arthritis. In: Weinstein GD, Gottlieb AB (eds) Therapy of moderate-to-severe psoriasis, 2nd edn. Dekker, New York Basel, pp 261\u2013283"},{"key":"1006_CR11","unstructured":"Holman J, Gardiner M, Wallis WJ et al. (2003) Tuberculosis reports with etanercept (Enbrel) therapy. Ann Rheum Dis 61 [Suppl 1]:167"},{"key":"1006_CR12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.0007-0963.2001.04529.x","volume":"146","author":"Iyer","year":"2002","unstructured":"Iyer S, Yamauchi P, Lowe NJ (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118\u2013121","journal-title":"Br J Dermatol"},{"key":"1006_CR13","unstructured":"Klareskog L, Moreland LM, Cohen SB et al. (2001) Global safety and efficacy of upto five years of etanercept (Enbrel) therapy. Arthritis Rheum 44 [Suppl]:S77 (Abstract 150)"},{"key":"1006_CR14","doi-asserted-by":"crossref","unstructured":"Kohno T, Stevens S, Louie J, Amgen Inc.,Thousand Oaks, CA, United States (2005) Adalimumab and infliximab bind to Fc-Receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. J Am Acad Dermatol 52 [Suppl]:36","DOI":"10.1016\/j.jaad.2004.10.158"},{"key":"1006_CR15","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","volume":"349","author":"Leonardi","year":"2003","unstructured":"Leonardi CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014\u20132022","journal-title":"N Engl J Med"},{"key":"1006_CR16","doi-asserted-by":"crossref","unstructured":"Loetscher H, Brockhaus M, Dembic Z et al. (1992) Two distinct human TNF receptors: purification, molecular cloning and expression. In: Osawa T, Bonavida B (eds): Tumor necrosis factor: structure-funcion, relationship and clinical application. Karger, Basel, pp 34\u201346","DOI":"10.1159\/000420768"},{"key":"1006_CR17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385\u2013390","journal-title":"Lancet"},{"key":"1006_CR18","unstructured":"Mease P, Kivitz A, Burch F et al. (2001) Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial. Arthritis Rheum 44 [Suppl]:S90\u2013A226"},{"key":"1006_CR19","unstructured":"Wyeth (2003) Moderne Rheumatherapie. Patienteninformation. Wyeth Europa Ltd. Berkshire, p 31"},{"key":"1006_CR20","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.4049\/jimmunol.151.3.1548","volume":"151","author":"Mohler","year":"1993","unstructured":"Mohler KM, Torrance DS, Smith CA et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548\u20131561","journal-title":"J Immunol"},{"key":"1006_CR21","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrd1175","volume":"2","author":"Palladino","year":"2003","unstructured":"Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-\u03b1 therapies: the next generation. Nat Rev Drug Discover 2:736\u2013746","journal-title":"Nat Rev Drug Discover"},{"key":"1006_CR22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","volume":"152","author":"Papp","year":"2005","unstructured":"Papp KA, Tyring S, Lahfa M et al. (2005) A global phase III randomized controlled trial of etanercept in psoriasis; safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304\u20131312","journal-title":"Br J Dermatol"},{"key":"1006_CR23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1084\/jem.174.6.1483","volume":"174","author":"Peppel","year":"1991","unstructured":"Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483\u20131489","journal-title":"J Exp Med"},{"key":"1006_CR24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/art1.10243","volume":"47","author":"Phillips","year":"2002","unstructured":"Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17\u201321","journal-title":"Arthritis Rheum"},{"key":"1006_CR25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/bmj.330.7493.716","volume":"330","author":"Rott","year":"2005","unstructured":"Rott S, Mrowietz U (2005) Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. Br Med J 330:716\u2013720","journal-title":"Br Med J"},{"key":"1006_CR26","doi-asserted-by":"crossref","unstructured":"Sfikakis PP (2002) Behcet\u2019s disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 [Suppl 2]:51\u201353","DOI":"10.1136\/ard.61.suppl_2.ii51"},{"key":"1006_CR27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"Schmitt","year":"2005","unstructured":"Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194\u2013199","journal-title":"Dermatology"},{"key":"1006_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","volume":"13","author":"Schottelius","year":"2004","unstructured":"Schottelius AJG, Moldawer LL, Dinarello CA et al. (2004) Biology of tumor necrosis factor-\u03b1-implications for psoriasis. Exp Dermatol 13:193\u2013222","journal-title":"Exp Dermatol"},{"key":"1006_CR29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0140-6736(02)07714-0","volume":"359","author":"Shakoor","year":"2002","unstructured":"Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579\u2013580","journal-title":"Lancet"},{"key":"1006_CR30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F","volume":"44","author":"Stone","year":"2001","unstructured":"Stone JH, Uhlfelder ML, Hellmann DB et al. (2001) Etanercept combined with conventional treatment in Wegener\u2019s granulomatosis: a six-months open-label trial to evaluate safety. Arthritis Rheum 44:1149\u20131154","journal-title":"Arthritis Rheum"},{"key":"1006_CR31","doi-asserted-by":"crossref","first-page":"P143","DOI":"10.1016\/j.jaad.2003.10.499","volume":"50","author":"Weinberg","year":"2004","unstructured":"Weinberg JM (2004) Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. J Am Acad Dermatol 50:P143","journal-title":"J Am Acad Dermatol"},{"key":"1006_CR32","unstructured":"Wozel G (Hrsg) (2004) UNI-MED Verlag AG. Bremen London Boston"},{"key":"1006_CR33","unstructured":"Wozel G (2005) Clinical review: psoriasis. Recent advances in the treatment of psoriasis. Hospital Pharmacy Europe, London, Sept.\/Oct. 2005:1\u20133"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-1006-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-005-1006-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-005-1006-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T06:37:30Z","timestamp":1683182250000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-005-1006-6"}},"subtitle":["Ein effektiver TNF-\u03b1-Antagonist zur Behandlung von Psoriasisarthritis und Psoriasis vulgaris","An effective TNF \u03b1-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["1006"],"URL":"https:\/\/doi.org\/10.1007\/s00105-005-1006-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}